WA-SPIE
11.1.2023 19:04:37 CET | Business Wire | Press release
The Awards Committee of SPIE, the international society for optics and photonics, today announced the recipients of its prestigious annual awards. Honoring transformative advancements in a variety of professional areas — including medicine, astronomy, lithography, optical metrology, optical design, and community leadership — the Society's awards recognize technical accomplishments as well as committed service to SPIE and support of its organizational mission.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230110005929/en/
Graham Reed is the 2023 recipient of the SPIE Gold Medal. (Photo: Business Wire)
SPIE Gold Medal: Graham T. Reed
For sustained and ongoing leadership in the silicon photonics field, particularly in the area of silicon photonics modulators, mid-IR silicon photonics, and integrated lidar.
SPIE President's Award: Patrick Meyrueis
For bringing together the European optics and photonics community, for encouraging students toward leadership activities, and for commitment to the Society in launching SPIE Photonics Europe.
SPIE Directors' Award: John Greivenkamp
A posthumous recognition, for longstanding service and leadership, by generously giving time, energy, enthusiasm, and wisdom to improve the Society and its educational impact on the global photonics community.
SPIE Mozi Award: Burn J. Lin
For great scientific achievements in immersion lithography for semiconductor manufacturing.
SPIE Britton Chance Award in Biomedical Optics: David Benaron
For the development of technologies and the founding and co-founding of companies utilizing biomedical optics that advanced the fields of medicine and medical technology.
SPIE Biophotonics Technology Innovator Award: Wei Min
For innovative work in stimulated Raman scattering microscopy, and for creating a new field of biophotonics.
SPIE Rudolf and Hilda Kingslake Award in Optical Design: Wilhelm Ulrich
For decades of transformative design solutions across a broad range of optical products including photographic lenses, microscopy objectives, medical-imaging instrumentation, laser optics, metrology systems, and infrared optics.
SPIE Harrison H. Barrett Award in Medical Imaging: Elizabeth Krupinski
For pioneering work in medical-image perception, teleradiology, telepathology, and being among the first to carry out image-perception studies in the new domain of digital pathology.
SPIE Harold E. Edgerton Award in High-Speed Optics: Tara Fortier
For pioneering contributions to the development of frequency combs based on mode-locked lasers and their applications in metrology.
SPIE Dennis Gabor Award in Diffractive Optics: Aydogan Ozcan
For seminal contributions to holography, lens-free holographic microscopy, and computational imaging that democratize advanced measurement systems.
SPIE George W. Goddard Award in Space and Airborne Optics: John MacKenty
For leading the design, development, testing, and operations of the Wide-Field Camera 3 on the Hubble Space Telescope, and for pioneering contributions to multi-object spectroscopy from space.
SPIE G. G. Stokes Award in Optical Polarization: Miguel A. Alonso
For pioneering work in the mathematical description of unconventional and non-paraxial polarization states.
SPIE Chandra S. Vikram Award in Optical Metrology: Zeev Zalevsky
For key contributions to the invention of a laser-based, remote, nano-vibrations sensor with primary applications in biomedical sensing and diagnostics.
SPIE Frits Zernike Award for Microlithography: Anthony Yen
For three decades of contributions in advancing microlithography technology, including developing extreme-ultraviolet lithography for high-volume manufacture of semiconductor integrated circuits.
SPIE Diversity Outreach Award: Danuta Sampson
For outstanding achievements in international educational outreach and leadership of activities promoting public engagement and diversity in science.
SPIE Maria Goeppert Mayer Award in Photonics: Volker Sorger
For pioneering research and outstanding innovations in the research and development of photonic and nanophotonic devices and systems, and for community leadership.
SPIE Maiman Laser Award: Bo Gu
For critical innovations in industrial laser technology with numerous seminal and sustained contributions, and for being an accomplished laser-industry leader with widely recognized commercial success.
SPIE Early Career Achievement Award — Academic Focus: Carmelo Rosales-Guzmán
For significant and innovative technical contributions to the field of structured light and its applications, as well as for the promotion of science in developing countries.
SPIE Early Career Achievement Award — Industry/Government Focus: Fenglin Peng
For contributions enabling the first LCD-based VR product on the market, and for innovating a compact Pancake VR with better image quality, higher efficiency, and easier mass-production.
SPIE María J. Yzuel Educator Award: Alexis Spilman Vogt
For excellence in optics-technician and associate’s-degree education and training, and for being a superb strategic educator in addressing the needs of an underserved market.
SPIE Aden and Marjorie Meinel Technology Achievement Award: Wolfgang Fink
For pioneering, sustained contributions to the development of transformational opto-medical examination and device technologies, with particular focus on visual prostheses for the blind, ophthalmology, and tele-ophthalmology.
The complete listing of the SPIE Society Awards and recipients is available here.
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom